Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Vividion Therapeutics, Inc.
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
April 25, 2024
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
February 06, 2024
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2023’ Award Winner by the San Diego Union-Tribune
November 21, 2023
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Names Shawn Rose as Chief Development Officer
September 07, 2023
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
March 23, 2023
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2022’ Award Winner by the San Diego Union-Tribune
November 21, 2022
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Announces Formation of Scientific Advisory Board
September 22, 2021
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target
June 24, 2021
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Appoints Christine Siu to Board of Directors
May 04, 2021
From
Vividion Therapeutics, Inc.
Via
Business Wire
Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments
April 20, 2021
From
Vividion Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.